Imagine living with hemophilia, where even minor injuries can lead to serious bleeding. This condition affects the blood's ability to clot, making everyday activities a challenge. For those with inhibitors, the situation is even more complex, as their bodies resist standard treatments. In a recent study, a new drug called concizumab was tested to see if it could help. Patients using concizumab experienced only about one bleeding episode over a year, compared to those not on the treatment, who faced many more. This means fewer interruptions in their daily lives and less anxiety about bleeding. While the results are promising, it's important to note that this treatment is still being evaluated, and more research is needed to confirm its long-term safety and effectiveness. However, for many living with hemophilia, concizumab offers hope for a more manageable life.
Could a New Treatment Change the Lives of People with Hemophilia?
Plain Language Summary
What this means for you:
Concizumab could be a game-changer for people with hemophilia, offering hope for fewer bleeding episodes. What this means for you:
Concizumab could be a game-changer for people with hemophilia, offering hope for fewer bleeding episodes. View Original Abstract ↓
Concizumab is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody intended for once-daily subcutaneous prophylactic treatment for people with hemophilia A or B with and without inhibitors. Results from the phase 3 explorer7 study confirmed superiority of concizumab prophylaxis over no prophylaxis in reducing the annualized bleeding rate (ABR) in people with hemophilia A or B with inhibitors (HAwI/HBwI). Male patients aged ≥12 years were randomized 1:2 to no prophylaxis (group 1) or concizumab prophylaxis (group 2), or nonrandomly allocated to concizumab prophylaxis (groups 3 and 4). After ≥24 weeks of treatment, patients in group 1 could switch to concizumab prophylaxis. At the 56-week cutoff (defined as when all patients in groups 2-4 had completed the visit at 56 weeks or permanently discontinued treatment), bleed-related efficacy, pharmacokinetics and pharmacodynamics, and safety were assessed. Of the 133 patients enrolled (HAwI, n = 80; HBwI, n = 53), 114 received concizumab prophylaxis (groups 2-4) and 19 were randomized to no prophylaxis (group 1). After ≥24 weeks, 13 patients from group 1 switched to concizumab. Median ABR for treated spontaneous and traumatic bleeding episodes in patients receiving concizumab was 0.8 (interquartile range [IQR], 0.0-3.2) at the 56-week cutoff, consistent with the low bleeding rates (median ABR, 0.0; IQR, 0.0-3.3) at the 32-week cutoff. Concizumab and free-TFPI concentration remained stable over time. No new safety concerns were reported. Longer-term (≥1 year) efficacy and safety results of concizumab prophylaxis for HAwI/HBwI were consistent with the 32-week cutoff results in explorer7. This trial was registered at www.clinicaltrials.gov as #NCT04083781.